Navigation Links
Senetek PLC Announces 2009 Annual General Meeting Voting Results
Date:12/15/2009

NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that shareholders had approved all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held on December 14, 2009. Voting results were as follows:




    Description of            Votes        Votes         Votes         Non-
     Matter                    For        Against       Withheld      Votes
    --------------            -----       -------       --------      -----

    Election of  Kerry
     Dukes as Director      6,165,331    1,363,208       71,963      45,300
    Receipt of Annual
     Accounts for 2008
     with Directors'
     Report, auditors'
     report on those
     accounts and
     approve the last
     Directors'
     remuneration
     report                 6,717,147      795,815       87,540      45,300
    Appointment of
     Macias Gini &
     O'Connell LLP and
     BDO Stoy Hayward
     as the Company's
     independent
     auditors for 2009      6,663,843      796,173      140,486      45,300



"We are pleased with the results of the voting and we thank our shareholders for their support" stated Frank J. Massino, Senetek Chairman and CEO.

Senetek PLC recently announced the hiring of Miller Tabak + Co., LLC as financial and strategic advisors. The Board has retained the firm to evaluate the Company's technology and business model and to make recommendations on the development of a plan that will benefit shareholders. As a result of this evaluation, Miller Tabak has made the following recommendations:

  • Consider changing the focus and direction of the Company and the current business model;
  • Identify potential business partners for merger and/or acquisition;
  • Raise additional capital.

The Company is currently in discussions with multiple investors and potential partners, however there is no assurance that these discussions will result in a completed transaction.

About Senetek PLC: Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology, most recently resulting in the development of kinetin, the active ingredient in the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites -- www.Senetekplc.com, www.Pyratine6.com and www.PyratineXR.com -- or call 877-SENETEK (United States and Canada) or 707-259-6278 (International Locations).

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

SOURCE Senetek PLC


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Implements New Corporate Communication Policy
2. Senetek PLC Reports Second Quarter 2009 Financial Results
3. Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany
4. Senetek PLC Reports First Quarter 2009 Financial Results
5. Senetek PLC Reports 2008 Financial Results
6. Dynamics Group AG Publishes Research Report on Senetek
7. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
8. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
9. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
10. Senetek PLC Announces Key Personnel Appointments
11. Senetek PLC Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known ... for in a show called "Front Page". One of the forthcoming episodes examines mammogram ... rates have plummeted in large part due to early detection. Like any other disease, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Findings from ... safety of CTL019, an investigational chimeric antigen receptor ... pediatric and young adult patients with B-cell acute ... an oral session at the 58th American Society ... 3, 4:00-5:30 p.m.). The global Phase II study ...
(Date:12/2/2016)... British Columbia , December 2, 2016 bioLytical Laboratories, ... de la Compañía, el INSTI HIV Self Test , a los miembros ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
Breaking Medicine Technology: